Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. - Wikidata - wikimedia - TriplyDB

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

http://www.wikidata.org/entity/Q34120902

about

Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery Venous thromboembolic disease Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Deep vein thrombosis: validation of a patient-reported leg symptom index Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review Anticoagulants in cancer Venous thromboembolism in cancer patients: an underestimated major health problem Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England Clinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Venous gangrene and cancer: a cool look at a burning issue.Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.[Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins].Cancer and Venous Thromboembolic Disease: A Review.Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy.The potential benefits of low-molecular-weight heparins in cancer patients Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs.Perioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgery Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study.Thromboembolic Complications and Prophylaxis Patterns in Colorectal Surgery.Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients.Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Venous thromboembolic events in minimally invasive gynecologic surgery.From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.

P2860

Q24187077-17F84014-5AD0-41A9-A0AD-14F4F8E7A75A Q24193749-DFD80457-85EB-4369-8BF5-29B25A78C422 Q24203816-53E31A04-A493-4F1C-977F-1BEDF4E2289B Q24235023-F3DCE6A3-3150-4C97-8586-404D2515EF43 Q24241736-51BDC112-7706-497B-A030-AFF5AC41D49D Q24631121-9A2E5CC0-C52A-4B4B-880D-572577CAB9D3 Q24632902-994832CB-3C3D-443A-B1F3-7E75258F7DD8 Q24632982-BFD32BFC-6315-49E5-B538-A38040DAE143 Q24806558-EA7F58BC-29F5-4C20-ADAE-869B3B72D90F Q26741697-703341F7-3D55-426A-8148-D1993D270EE2 Q26753853-0F4D9569-6A17-4E93-A079-01C3C51193F0 Q26825228-3F3EFBF8-7F33-4C05-94FF-975089F67A3B Q26852015-1A9AF6ED-EB8A-4EA8-A3C8-3AC61FC7CD75 Q30572499-121BFE57-E426-4118-8B08-A7D5D9265909 Q31034323-7192DD64-F7F0-4687-B7E3-DCEF5EAD8B19 Q33360866-4D22A167-3C0E-4F22-BDBC-5F746EC64481 Q33360869-2F70FD8F-E50F-427F-9688-39F28998A628 Q33372266-DF1ABD9A-AE08-49EB-BF17-27D57509C580 Q33374683-C92CD0EA-45E0-4273-9CCE-F0C97C7D62DE Q33389637-54BEE0C1-5E3A-41B1-AB6C-B62A6344A36E Q33399333-4C77905D-8191-4FE4-A69E-7E6BB4274758 Q33413690-3ADAF5B6-B6CC-4A91-9497-0BFC2842D504 Q33439089-863E1C3D-06CA-4A72-BF80-736C31939156 Q33561213-3926DF3D-78F4-4440-8963-779C93FFCC7B Q33620158-23A6A144-A78B-446B-B0E7-1440FE28C54E Q33672186-B665A915-7199-4A70-904C-952AA1D5398B Q33698360-A0704EE7-BA03-4D91-BD6A-E5313A052348 Q33763866-3779E847-CF48-4F7D-8BB2-7B988C0542D7 Q33912800-83E95C69-29F6-4257-9804-B0B92B4B5613 Q34211162-6F50A292-A536-4558-9B56-B0ABD1F7F26C Q34324192-2C9A9488-1521-4A07-AAF6-F9D3F6C3AA9C Q34480121-9D21A529-E5EA-4E0F-9305-67ABE1F263F6 Q34644267-FA5543C5-248B-4E7F-B1DB-E01F0D8C3F28 Q34733377-198FB142-2415-4606-A29B-5E0F0ED32DDA Q34959822-DF8C45EA-DCD7-4A70-B93D-AEE2EA6A0BE4 Q35016892-5849EABE-580D-45C2-977C-7B947627CEA0 Q35169184-CE137C3A-1F12-42E3-8D1C-EE3E9DCE398A Q35174604-BD529319-0F2E-4B13-BE50-02AF526DB481 Q35180682-F8768A68-9B54-48DA-AFC7-2AFA417710D2 Q35181616-B65818BB-89E5-4C4D-BA59-3D3AB56C8943

P2860

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

http://www.wikidata.org/entity/Q34120902

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Duration of prophylaxis agains ...... arin after surgery for cancer.

@ast

Duration of prophylaxis agains ...... arin after surgery for cancer.

@en

Duration of prophylaxis agains ...... arin after surgery for cancer.

@nl

type

label

Duration of prophylaxis agains ...... arin after surgery for cancer.

@ast

Duration of prophylaxis agains ...... arin after surgery for cancer.

@en

Duration of prophylaxis agains ...... arin after surgery for cancer.

@nl

prefLabel

Duration of prophylaxis agains ...... arin after surgery for cancer.

@ast

Duration of prophylaxis agains ...... arin after surgery for cancer.

@en

Duration of prophylaxis agains ...... arin after surgery for cancer.

@nl

P1433

Q34120902-64310B5A-74C3-4AEB-AA73-097DD7C1A3C5

P1476

Q34120902-DDEB0D5C-4AE2-47CC-98A7-250B5D11E13B

P2093

Q34120902-4F6F59AF-18C4-4325-8E02-5AA3A165D906

Q34120902-85B8A0CE-978D-4B1B-975D-3A4B508AC20A

Q34120902-B6F8C161-4577-4525-908F-8053E4CBCC21

Q34120902-C0D10DCC-C303-4E79-9FF4-264ECC486F7D

Q34120902-C8EAD78B-E9CA-4419-A4A8-E7345C97FDC0

Q34120902-D00D3A02-0312-45CE-93BF-D11843828212

Q34120902-D4545405-AC99-47A5-B768-CFA889BD1124

Q34120902-F562D142-CDEB-4752-9257-7452C8E400CE

P304

Q34120902-41A11E90-A2D0-468B-9DFA-AB289C72EC47

P31

Q34120902-2725F20B-DFBB-4FDB-BF29-86B716E8AEDC

P356

Q34120902-E7235C2C-289C-4F2D-BC68-509E199F26F8

P407

Q34120902-BA65D6E1-8439-4FEE-8E9F-B386AD66655B

P433

Q34120902-3FB061DC-E85E-4E6B-835F-A41CA7AB347A

P478

Q34120902-51327D19-D1AD-47DF-AA10-33AE621AE965

P577

Q34120902-49FF7C0E-F35E-421A-ACED-C3235D1549CD

P698

Q34120902-E9D77F27-5AC6-4494-8988-259E603AB530

P356

P1433

The New England Journal of Medicine

P1476

Duration of prophylaxis agains ...... arin after surgery for cancer.

@en

P2093

Alexander T Cohen

http://www.w3.org/2001/XMLSchema#string

Amiram Eldor

http://www.w3.org/2001/XMLSchema#string

Anne Le Moigne-Amrani

http://www.w3.org/2001/XMLSchema#string

David Bergqvist

http://www.w3.org/2001/XMLSchema#string

ENOXACAN II Investigators

http://www.w3.org/2001/XMLSchema#string

Flavia Dietrich-Neto

http://www.w3.org/2001/XMLSchema#string

Giancarlo Agnelli

http://www.w3.org/2001/XMLSchema#string

Paul E Nilsson

http://www.w3.org/2001/XMLSchema#string

P304

975-980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA012385

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11919306

http://www.w3.org/2001/XMLSchema#string